GSK plc Sponsored ADR (GSK)
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
GSK plc GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development.
Will GSK Stock Rebound To Its 2022 Highs Of $47?
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over this period.
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac (CVAC).
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccines.
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for common stock trades.
GSK takes full control of flu vaccine programme in €1.45bn deal
GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Germany's CureVac, the UK drugs giant will be ceded the rights to develop, manufacture, and sell these vaccines generated by the partnership.
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
GSK buys full rights to make COVID, influenza vaccines from CureVac
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
